Less than 10% of patients who could benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it publishes its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to this class of drugs.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to broad availability to the jabs that can assist patients in reducing substantial weight, explains the body.
Despite the present most favorable case, the production of such drugs might only reach around 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation encourages nations and manufacturers to increase access, by strategies such as voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The injections imitate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so users reduce food intake.
Patients commonly start to lose weight after several weeks of beginning the weekly injections.
Research indicates users may put most of the weight back on a year later of stopping the medication, because their typical food cravings come back.
To be carrying excess weight raises your likelihood for contracting health problems, including type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, per the WHO.
Digital marketing strategist with over a decade of experience in SEO and content creation, passionate about helping businesses thrive online.
Joshua Manning
Joshua Manning
Joshua Manning
Joshua Manning
Joshua Manning
Joshua Manning